Trump's 100% Pharma Tariff: Sun Pharma, Glenmark Face Impact

Introduction to the New Tariff Policy

The United States administration has announced a significant policy shift, planning to impose a 100% tariff on all imported branded and patented pharmaceutical products. The new levy, set to take effect from October 1, 2025, has sent ripples through the global pharmaceutical industry, with Indian drugmakers watching closely. The policy includes a crucial exemption: the tariff will not apply to companies that are actively building or have started construction on manufacturing facilities within the U.S. This move is seen as an effort to encourage domestic drug production. The announcement triggered an immediate negative reaction in the Indian stock market, particularly affecting pharmaceutical stocks with exposure to the U.S. branded drug market.

Immediate Market Reaction

Following the announcement, Indian pharmaceutical stocks experienced a sharp decline. The NIFTY PHARMA index fell by approximately 2.36% to 21,458.75, with all of its 20 constituent stocks trading in the red. Sun Pharmaceutical Industries Ltd., India's largest drugmaker, was among the hardest hit, with its shares tumbling by over 5% to a 52-week low of Rs 1,547.25. Other major players, including Glenmark Pharmaceuticals, Dr. Reddy's Laboratories, Gland Pharma, and Biocon, also saw their stock prices fall by up to 6%. The market's reaction reflects investor concerns about the potential impact on earnings for companies with significant revenue from patented products sold in the U.S.

The Generic Shield: Why Most Indian Exporters are Insulated

Despite the market jitters, analysts suggest that the immediate impact on the majority of Indian pharmaceutical companies will be limited. This is because India's pharmaceutical exports to the U.S. are overwhelmingly dominated by generic drugs, which are currently exempt from the proposed tariffs. India, often called the 'Pharmacy of the World,' is a critical supplier of affordable medicines, accounting for about 40% of generic drug volume in the U.S. market. Generics make up over 90% of prescriptions filled in the U.S. but represent a small fraction of the country's total healthcare spending. Financial institutions like Goldman Sachs and rating agencies like Crisil have noted that since the tariffs specifically target branded and patented products, the core business of most Indian exporters remains shielded.

Sun Pharma: A Closer Look at the Exposure

Sun Pharma stands out as one of the Indian companies most exposed to the new tariff regime due to its substantial presence in the U.S. specialty drug market. In the fiscal year 2025, the company's U.S. sales accounted for 31% of its total revenue. More importantly, its global revenue from patented products reached $1.2 billion, with an estimated 85-90% of these sales originating from the U.S. Specialty brands such as Ilumya, Cequa, and Sezaby fall directly under the purview of the new tariffs. However, an analysis by Jefferies suggests a potential mitigating factor. Some of Sun Pharma's key innovative products are manufactured in South Korea or the European Union, which have existing trade agreements with the U.S. This could potentially cap the effective tariff on these specific products at a lower rate, such as 15%.

Glenmark's Direct Hit with Ryaltris

Glenmark Pharmaceuticals is another company facing a direct impact. The company has recently taken full control of the commercialization of its branded allergy drug, Ryaltris, in the U.S. This marks Glenmark's first branded product launched directly in the American market. Since Ryaltris is manufactured in Switzerland and the company has no immediate plans to construct a U.S. manufacturing facility, the product is directly vulnerable to the full 100% tariff. This situation highlights the selective nature of the tariff's impact, penalizing companies that rely on foreign manufacturing for their patented U.S.-bound products.

US Revenue Exposure Across the Sector

The level of risk for Indian pharma companies varies depending on their revenue mix and exposure to the U.S. market. While generics provide a buffer for many, those with a growing portfolio of specialty or complex drugs face greater uncertainty. The table below outlines the U.S. revenue exposure for some of the key players.

Analyst Perspectives and Future Outlook

Analysts generally agree that while the headline risk is significant, the near-term earnings impact on the Indian pharma sector as a whole is manageable. The primary concern is the ambiguity surrounding the policy's future scope. There are fears that the tariffs could eventually be expanded to include complex generics or other specialty medicines, which would broaden the impact considerably. Some experts also question the long-term sustainability of such a steep tariff, arguing it would substantially increase healthcare costs for American consumers and the government. The exemption for companies investing in U.S. manufacturing offers a clear, though capital-intensive, path to mitigate the tariff's effects. The industry is now awaiting further clarification from the U.S. administration to assess the full implications.

Conclusion

The U.S. administration's decision to implement a 100% tariff on branded and patented drugs is a targeted measure that will selectively affect Indian pharmaceutical exporters. Companies like Sun Pharma and Glenmark, with established and growing specialty portfolios in the U.S., face the most direct and immediate challenges. The broader Indian pharma industry, with its strong focus on generic exports, remains largely insulated for now. However, this policy introduces a new layer of uncertainty into the world's largest pharmaceutical market, and its evolution will be a key factor for Indian drugmakers' future strategies.